StockNews.AI
CLLS
StockNews.AI
165 days

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

1. Cellectis will report Q4 and annual financial results on March 13, 2025. 2. An investor conference call is scheduled for March 14, 2025. 3. Cellectis specializes in gene-editing therapies and CAR T-cell treatments. 4. The company controls the entire gene therapy value chain in-house.

4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements typically have mixed effects; historical examples include earnings surprises impacting stock before and after announcements.

How important is it?

Investors will analyze earnings for insights into CLLS's operational performance and future prospects.

Why Short Term?

Earnings announcements often lead to immediate trading adjustments based on results.

Related Companies

CRSPEDITSGMO
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: +1-203-518-9708 Conference ID: CLLS24 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706599&tp_key=4524940f8f About Cellectis      Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X. TALEN® is a registered trademark owned by Cellectis.  For further information on Cellectis, please contact:      Media contacts:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact:        Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com        20250307_FY 2024 earnings call announcement_ENGLISH

Related News